公开(公告)号：US20210087293A1

公开(公告)日：2021-03-25

申请号：US17010354

申请日：2020-09-02

Applicant: Dyax Corp.

Inventor： Daniel J. Sexton ,  Burt Adelman ,  Yung Chyung ,  Christopher TenHoor ,  Jon A. Kenniston ,  Ryan Faucette ,  Ryan Iarrobino ,  Joseph Biedenkapp

IPC: C07K16/40

Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

公开(公告)号：US20180298110A1

公开(公告)日：2018-10-18

申请号：US15562671

申请日：2016-03-30

Applicant: Dyax Corp. ,  SYNVINA C.V.

Inventor： Yung Chyung ,  Burt Adelman ,  Daniel J. Sexton

IPC: C07K16/40 ,  A61P7/10

Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack.

公开(公告)号：US20150362493A1

公开(公告)日：2015-12-17

申请号：US14761690

申请日：2014-01-17

Applicant: DYAX CORP.

Inventor： Daniel J. Sexton ,  Ryan Faucette ,  Jon A. Kenniston ,  Gregory P. Conley ,  Andrew Nixon ,  Christopher TenHoor ,  Burt Adelman ,  Yung Chyung

IPC: G01N33/573 ,  C07K7/06 ,  C07K16/40

CPC classification number: G01N33/5735 ,  C07K7/06 ,  C07K16/36 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76 ,  G01N2333/745 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/52 ,  G01N2800/70

Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Abstract translation: 本公开提供了评估受试者的方法，例如，基于pKal介导的或缓激肽介导的病症的风险或患有pKal介导的或缓激肽介导的病症的受试者，基于样品中完整和/或切割的激肽原的值（例如，百分比） 学科。 提供的方法允许对血浆激肽释放酶介导的血管性水肿（KMA）或由pKal介导的其它疾病的患者进行分析，其可用于评估和治疗。 这样的方法可以涉及使用优先结合切割的激肽原或完整激肽原的检测剂。

公开(公告)号：US20180362664A1

公开(公告)日：2018-12-20

申请号：US16061103

申请日：2016-12-09

Applicant: Dyax Corp.

Inventor： Burt Adelman ,  Yung Chyung ,  Jennifer Schranz

IPC: C07K16/40 ,  A61K39/395 ,  A61P29/00

Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.

公开(公告)号：US20170002094A1

公开(公告)日：2017-01-05

申请号：US15113297

申请日：2015-01-21

Applicant: DYAX CORP.

Inventor： Daniel J. Sexton ,  Burt Adelman ,  Yung Chyung ,  Christopher TenHoor ,  Jon A. Kenniston ,  Ryan Faucette ,  Rayan larrobino ,  Joe Biedenkapp

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Abstract translation: 本文提供血浆激肽释放酶结合蛋白，例如结合活性血浆激肽释放酶的抗体以及使用这些蛋白质治疗遗传性血管性水肿的方法。